Industry
EGEN, Inc.
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
Failure Rate
66.7%
2 terminated/withdrawn out of 3 trials
Success Rate
33.3%
-53.2% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 1
3(100.0%)
3Total
Phase 1(3)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT01300858Phase 1Terminated
A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients
Role: lead
NCT00473954Phase 1Completed
Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer
Role: lead
NCT00137865Phase 1Terminated
Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer
Role: lead
All 3 trials loaded